<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00477373</url>
  </required_header>
  <id_info>
    <org_study_id>DPKOT_L_01567</org_study_id>
    <nct_id>NCT00477373</nct_id>
  </id_info>
  <brief_title>Gulf Evaluation of VAlproate (Depakine Chrono) in maNia Study</brief_title>
  <acronym>GEVANS</acronym>
  <official_title>Gulf Evaluation of VAlproate (Depakine Chrono) in maNia Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy of Di-valproate in Bipolar I patients suffering from a manic episode
      according to DSM IV (APA 1994) over a 12 weeks period of treatment.

      To evaluate the clinical safety of Di-valproate.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The mean change in the Clinical Global Impressions Scale for Bipolar Disorder (CGI-BP)Severity score as well as the change in CGI-BP.</measure>
    <time_frame>D0, D21 and D-end</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of responders defined by a decrease of at least 50% of the CGI-BP.</measure>
    <time_frame>D0 and D-end</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of responders defined by a decrease of at least 50% of the CGI-BP.</measure>
    <time_frame>D0 and D21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve 50% and 30% improvement in the CGI-BP score.</measure>
    <time_frame>From randomization to the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to a sustained improvement in the CGI-BP.</measure>
    <time_frame>From randomization to the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to antidepressants use.</measure>
    <time_frame>From randomization to the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to drop-out for any reason.</measure>
    <time_frame>From randomization to the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety :Occurrence of any side effect leading to treatment discontinuation.</measure>
    <time_frame>From inform consent signed until patient's recovery or stabilization</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If the daily dose does not exceed 1000 mg, Depakine CHRONO can be administered once a day. If the dose is greater than 1000 mg/day, Depakine CHRONO will be administered in a bid regimen: one tablet in the morning and one tablet in the evening.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>depakine chrono</intervention_name>
    <description>Depakine Chrono 500 mg</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In or out patients

          -  Patients with a current diagnosis of Bipolar I Disorder according to DSM IV (296)

          -  Patients suffering from a current manic episode or mixed episode

        Exclusion Criteria:

          -  Patients who participated in a clinical trial within the three preceding months

          -  Patients with a history of valproate intolerance defined as valproate discontinuation
             due to medically significant adverse effects.

          -  Patients with a CNS neoplasm, demyelinating disease, degenerative neurological
             disorder, active CNS infection or any progressive disorder

          -  Patients with a history of seizure disorder, cerebral vascular disease, structural
             brain damage from trauma, clinically significant focal neurological abnormalities,
             known EEG with frank paroxysmal activity or a known CT scan of the brain demonstrating
             gross structural abnormalities

          -  Patients with uncontrolled gastro-intestinal, renal, hepatic, endocrine,
             cardiovascular, pulmonary, immunological or hematological disease

          -  Patients with acute or chronic hepatitis

          -  Patients with current or past pancreatitis

          -  Patients with recent history (3 months or less) of substance or alcohol dependence
             according to DSM IV

          -  Pregnancy or lactation. Women of child bearing age should be using a reliable
             contraceptive method

          -  Patients that require more than 325 mg of aspirin per day

          -  Patients with a medical condition which requires the continuous use of medication
             which could interfere with the evaluation of safety or efficacy of valproate :
             anticonvulsant or anticoagulant therapy, MAO inhibitors, zidovudine

          -  Patients having received any depot neuroleptic within six weeks prior to baseline

          -  Patients who received antidepressant drugs within 5 days before baseline and patients
             who received fluoxetine within 20 days

          -  Patients judged by the investigator to have serious risk of suicide

          -  Patients necessitating an Electro Convulsive Therapy

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hisham - MAHMOUD, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi-aventis administrative office Gulf</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-aventis administrative office</name>
      <address>
        <city>Bahrain</city>
        <country>Bahrain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-aventis administrative office</name>
      <address>
        <city>Kuwait</city>
        <country>Kuwait</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Muscat</city>
        <country>Oman</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-aventis administrative office</name>
      <address>
        <city>Qatar</city>
        <country>Qatar</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bahrain</country>
    <country>Kuwait</country>
    <country>Oman</country>
    <country>Qatar</country>
  </location_countries>
  <removed_countries>
    <country>United Arab Emirates</country>
  </removed_countries>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2007</study_first_submitted>
  <study_first_submitted_qc>May 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2007</study_first_posted>
  <last_update_submitted>December 18, 2008</last_update_submitted>
  <last_update_submitted_qc>December 18, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2008</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

